Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Group Study To Investigate The Safety, Toleration And Pharmacokinetics Of Multiple Oral Doses Of PF-04531083 In Healthy Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: PF-04531083 or Placebo

First Posted Date: 2009-11-13

Last Posted Date: 2010-04-16

Lead Sponsor: Pfizer

Target Recruit Count: 40

Registration Number: NCT01012310

Locations: 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium

A Study Evaluating The Absorption Of Varenicline Into The Body From A Varenicline Patch Applied To The Skin

Phase 1

Completed

Conditions: Smoking Cessation

Interventions: Drug: varenicline free base patch

First Posted Date: 2009-11-13

Last Posted Date: 2009-12-21

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT01013454

Locations: 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium

First In Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04427429 Administered Intravenously To Healthy Adult Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: PF-04427429

First Posted Date: 2009-11-11

Last Posted Date: 2018-12-04

Lead Sponsor: Pfizer

Target Recruit Count: 24

Registration Number: NCT01011296

Locations: 🇺🇸
Pfizer Investigational Site, Phoenix, Arizona, United States

Study Evaluating Single Dose Of ILV-095 In Psoriasis Subjects

Phase 1

Terminated

Conditions: Plaque Psoriasis

Interventions: Drug: ILV-095 300 mg in a 4 to 1 ratio

First Posted Date: 2009-11-10

Last Posted Date: 2024-07-03

Lead Sponsor: Pfizer

Target Recruit Count: 39

Registration Number: NCT01010542

Locations: 🇺🇸
Cetero Research, Miami Gardens, Florida, United States
🇺🇸
Miami Research Associates, Inc., South Miami, Florida, United States
🇺🇸
MRA Clinical Research, South Miami, Florida, United States

and more 6 locations

Study Evaluating The Efficacy And Safety Of SBI-087 In Seropositive Subjects With Active Rheumatoid Arthritis

Phase 2

Completed

Conditions: Active Rheumatoid Arthritis

Interventions: Drug: SBI-087
Drug: Placebo

First Posted Date: 2009-11-06

Last Posted Date: 2013-12-03

Lead Sponsor: Pfizer

Target Recruit Count: 210

Registration Number: NCT01008852

Locations: 🇪🇸
Pfizer Investigational Site, Sevilla, Spain

Caverject User Study

Phase 3

Completed

Conditions: Erectile Dysfunction

Interventions: Other: delivery system

First Posted Date: 2009-11-06

Last Posted Date: 2012-04-06

Lead Sponsor: Pfizer

Target Recruit Count: 48

Registration Number: NCT01008605

Locations: 🇺🇸
Pfizer Investigational Site, Overland Park, Kansas, United States

A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy

Phase 2

Completed

Conditions: Excessive Daytime Sleepiness
Narcolepsy

Interventions: Drug: Placebo
Drug: PF-03654746

First Posted Date: 2009-11-01

Last Posted Date: 2014-05-09

Lead Sponsor: Pfizer

Target Recruit Count: 95

Registration Number: NCT01006122

Locations: 🇺🇸
Pfizer Investigational Site, Houston, Texas, United States

Effect of PF-04360365 On ABETA In Patients With Alzheimer's Disease And Healthy Volunteers

Phase 1

Completed

Conditions: Alzheimer's Disease

Interventions: Biological: PF-04360365
Drug: Placebo

First Posted Date: 2009-11-01

Last Posted Date: 2012-09-26

Lead Sponsor: Pfizer

Target Recruit Count: 17

Registration Number: NCT01005862

Locations: 🇸🇪
Pfizer Investigational Site, Stockholm, Sweden

A Safety, Tolerability, And Pharmacokinetic Trial With CVX-241 In Patients With Advanced Solid Tumors

Phase 1

Terminated

Conditions: Advanced Solid Tumors

Interventions: Drug: CVX-241

First Posted Date: 2009-10-30

Last Posted Date: 2015-11-20

Lead Sponsor: Pfizer

Target Recruit Count: 31

Registration Number: NCT01004822

Locations: 🇺🇸
Premiere Oncology of Arizona, Scottsdale, Arizona, United States
🇺🇸
Premiere Oncology, A Medical Corporation, Santa Monica,, California, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy

Phase 1

Completed

Conditions: Eye Diseases
Retinal Degeneration
Macular Degeneration
Age-Related Maculopathy
Age-Related Maculopathies

Interventions: Biological: RN6G
Biological: Placebo

First Posted Date: 2009-10-29

Last Posted Date: 2022-05-12

Lead Sponsor: Pfizer

Target Recruit Count: 24

Registration Number: NCT01003691

Locations: 🇺🇸
Retinal Diagnostic Center, Campbell, California, United States
🇺🇸
American Institute of Research (Administrative Only), Los Gatos, California, United States
🇺🇸
Neurology Center Rai Kumar, San Jose, California, United States

and more 21 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy